Honduras Passes In a WHO Trial Of Coronavirus Treatment

Honduras was approved in the Solidarity clinical trial of the World Health Organization (WHO) on treatments against COVID-19, a disease that has caused the death of almost fifty people and more than 400 infected in the country since March, reported this Friday an official source.


“This important project can find the light to reduce the high mortality that this disease is producing among Hondurans, in the region and worldwide,” scientist Marco Tulio Medina, one of the Honduran professionals involved in the activity, told Efe in Tegucigalpa. .


Medina indicated that the coordinator of the WHO clinical trial, Ana María Henao Restrepo, told the group of researchers from Honduras that this country is the first in Central America that would be starting to use four drugs for its COVID-19 patients.

Those medications, which are already being evaluated in five Honduran hospitals, are: remdesivir, chloroquine, lopinavir or lopinvir and interferon.

“There are international reports that remdesivir may be a highly promising drug, as previously hydroxychloroquine and chloroquine had previously been,” Medina said.

Intensivists, internists, infectious diseases and pulmonologists, led by the Ministry of Public Health, the National Autonomous University of Honduras and Medina himself, participate in the group of national researchers, with the advice of renowned Honduran scientist Salvador Moncada, who lives in London.

Medina noted that last Wednesday a teleconference was held with staff of the WHO Solidarity Project to evaluate treatments in relation to people with severe cases of COVID-19.

The two responsible for carrying out the project in Honduras are the Deputy Minister of Health, Nery Cerrato, and Medina, as scientific coordinator.


“It is important to highlight that this study has been approved with the highest bioethical standards of the Infectious and Zoonotic Diseases Ethics Committee of the School of Microbiology of the National Autonomous University of Honduras,” said Medina.

In his opinion, the example of Honduras should also motivate the rest of the Central American countries to join the initiative, which “will allow us to find a scientific answer as to the best treatments to use for this condition.”

“In the case of Honduras, it is seriously producing the highest percentage mortality or case fatality in Latin America. At the moment it represents 9% case fatality, much higher than what is also happening in other Central American countries,” he emphasized.

He added that it is a matter of finding a treatment that can reduce this mortality and that COVID-19 cases worsen, given the scientific evidence of the best treatment to follow.

The Solidaridad clinical trial has been implemented in Argentina, Canada, Spain, France, Iran, Norway, South Africa, Switzerland and Thailand.

The results will depend a lot on the research, on evaluating which is the best treatment; The larger the sample, the faster the response is reached, because statistically significant data are established on the best treatment to follow to reduce mortality and also on the hospital stay, said the Honduran scientist.

Honduras has some of the indicated medications, but it is asking to have them all, because based on the projection that it has, it could not provide complete coverage if a large number of people reach hospitals.

Medina pointed out that Dr. Henao Restrepo has said that if chloroquine or lopinavir are available in Honduras, any doctor can use them, within the protocol.

Medications can only be administered in the context of the study.

In the case of Honduras, the ethical, bioethical part, approval of the Government, doctors and the Honduran infrastructure have been complied with, while the WHO would send the medications, Medina said.



Leave a Reply

Your email address will not be published.

65 − 64 =